AFFECT: A prospective, open-label, multicenter trial to evaluate the feasibility and safety of a short-term treatment with subcutaneous certoparin in patients with persistent non-valvular atrial fibrillation

Clinical Research in Cardiology

Volumn 97, Issue 6, 2008, Pages 389-396

  Tebbe, Ulrich ^a   Oeckinghaus, Ralph ^a   Appel, Karl Friedrich ^b   Heuer, Hubertus ^c   Haake, Hendrik ^d   Eggers, Egbert ^e   Seidel, Karlheinz ^f   Adams, Jan ^g   Harenberg, Job ^h  

^a KLINIKUM LIPPE DETMOLD   (Germany)

^b Ambulantes Herzzentrum Kassel   (Germany)

^c ST JOHANNES HOSPITAL   (Germany)

^d Krankenhaus St Franziskus   (Germany)

^e Kreiskrankenhaus Torgau ^*  (Germany)

^f KLINIKUM LUDWIGSHAFEN   (Germany)

^g NOVARTIS PHARMA GMBH   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anticoagulation; Atrial fibrillation; Cardioversion; Certoparin; Low molecular weight heparin; Transoesophageal echocardiography

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CERTOPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVERSION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; SHORT COURSE THERAPY; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSIENT ISCHEMIC ATTACK;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ELECTRIC COUNTERSHOCK; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 46249109499     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-008-0644-y     Document Type: Article

References (20)

1. Bechtold H, Janssen D (2004) Anticoagulation with low-molecular-weight heparin in patients with heart diseases. Eur J Med Res 9:186-198
2. Becker T, Kleemann T, Strauss M, Doenges K, Schneider S, Senges J, Seidl K (2007) Long-term prognosis after cardioversion of the first episode of symptomatic atrial fibrillation: a condition believed to be benign revised. Clin Res Cardiol
3. Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, Sotirov I, Thomas D (2001) Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 103:658-663
4. de Luca I, Sorino M, De Luca L, Colonna P, Del Salvatore B, Corliano L (2005) Pre- and post-cardioversion transesophageal echocardiography for brief anticoagulation therapy with enoxaparin in atrial fibrillation patients: a prospective study with a 1-year follow-up. Int J Cardiol 102:447-454
5. Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM (1988) The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 28:609-618
6. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114:e257-e354
7. Harenberg J, Riess H, Buller HR, Brom J, Weidinger G, Huisman MV (2003) Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin. Haematologica 88:1157-1162
8. Hylek EM, Singer DE (1994) Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 120:897-902
9. Hylek EM, Skates SJ, Sheehan MA, Singer DE (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335:540-546
10. Kirchmaier CM, Wolf H, Schafer H, Ehlers B, Breddin HK (1998) Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-study group. Int Angiol 17:135-145
11. Kleemann T, Becker T, Donges K, Vater M, Gut B, Schneider S, Senges J, Seidl K (2007) The prognostic impact of successful cardioversion of atrial fibrillation in patients with organic heart disease. Clin Res Cardiol 96:103-108
12. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, Erbel R et al (2001) Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344:1411-1420
13. Klein AL, Jasper SE, Katz WE, Malouf JF, Pape LA, Stoddard MF, Apperson-Hansen C, Lieber EA (2006) The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicentre study. Eur Heart J 27:2858-2865
14. Lethen H, Oberst P, Bermes A, Zuercher F, Kersting S, Lambertz H (2006) Longterm results after TEE-guided electrical cardioversion of atrial fibrillation using a short term anticoagulation strategy with enoxaparin. Relevance of LAA flow for an event free outcome. Circulation 114:361
15. Murray RD, Deitcher SR, Shah A, Jasper SE, Bashir M, Grimm RA, Klein AL (2001) Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation. J Am Soc Echocardiogr 14:200-208
16. Rosenkranz S, Maier LS, Maack C, Bohm M (2007) Hotline update of clinical trials and registries presented at the German Cardiac Society Meeting 2007: 2L-Registry, Kardio-Pro, EVER, AFFECT, VTACH, ARTS II, OPTAMI, PEPCAD I, PEPCAD II, GERSHWIN, SPICE, FIX-CHF and CREDIT. Clin Res Cardiol 96:457-468
17. Schmidt-Lucke C, Paar WD, Stellbrink C, Nixdorff U, Hofmann T, Meurer J, Grewe R, Daniel WG et al (2007) Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the anticoagulation in cardioversion using enoxaparin (ACE) trial. Thromb Res 119:27-34
18. Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mugge A et al (2004) Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the anticoagulation in cardioversion using enoxaparin (ACE) trial. Circulation 109:997-1003
19. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL et al (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-1833
20. Young E, Wells P, Holloway S, Weitz J, Hirsh J (1994) Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 71:300-304